Intensity Therapeutics grants 5,500 director stock options

Intensity Therapeutics, Inc. director Mark A. Goldberg received a grant of stock options covering 5,500 shares of common stock.

Rhea-AI Filing Summary

Intensity Therapeutics, Inc. director Mark A. Goldberg received a grant of stock options covering 5,500 shares of common stock. The options have an exercise price of $4.90 per share, expire on 2036-07-16, and are held directly. They will vest in four equal annual installments beginning on July 16, 2026, subject to his continued service.

Insider Trade Summary

Grant/Award: 5,500 shares

Grant/Award 1 txn

Insider GOLDBERG MARK A

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy Common Stock) F1	5,500	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy Common Stock) — 5,500 contracts (Direct)

Footnotes (1)

1. F1. This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on July 16, 2026.

Key Figures

Stock options granted: 5,500 options Exercise price: $4.90 per share Expiration date: 2036-07-16 +2 more

5 metrics

Stock options granted 5,500 options Grant to director Mark A. Goldberg on 2026-07-16

Exercise price $4.90 per share Conversion or exercise price of the stock options

Expiration date 2036-07-16 Date on which the granted options expire

Vesting installments 4 equal annual installments Vesting schedule beginning July 16, 2026, subject to continued service

Derivative holdings after grant 5,500 options Total derivative securities held following the reported transaction

Key Terms

Stock Option (right to buy Common Stock), conversion or exercise price, derivative, vest

4 terms

Stock Option (right to buy Common Stock) financial

"security_title: "Stock Option (right to buy Common Stock)""

conversion or exercise price financial

""conversion_or_exercise_price": "4.9000" for the option grant"

derivative financial

""transaction_type": "derivative" for the reported option grant"

A derivative is a financial contract whose value depends on the price or performance of another asset or measure — for example a stock, index, interest rate, commodity, or currency. Investors use derivatives like insurance or leveraged bets to hedge risk, speculate, or gain exposure without owning the underlying asset; they can protect portfolios but also amplify losses and introduce counterparty and market risk.

vest financial

"This option will vest ... in four, equal, annual installments"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did INTENSITY THERAPEUTICS (INTS) report for Mark A. Goldberg?

Mark A. Goldberg reported receiving a grant of stock options for 5,500 shares of Intensity Therapeutics common stock. The Form 4 identifies this as a derivative transaction classified as a grant, award, or other acquisition of options held directly.

What is the exercise price and term of Mark A. Goldberg’s INTS stock options?

The granted options carry an exercise (conversion) price of $4.90 per share and an expiration date of 2036-07-16. These terms define the price Goldberg may pay per share and the final date on which the options can be exercised.

How do Mark A. Goldberg’s Intensity Therapeutics (INTS) options vest?

The options will vest in four equal annual installments beginning on July 16, 2026. Vesting is expressly conditioned on Goldberg’s continued service with Intensity Therapeutics, meaning unvested portions depend on ongoing service to the company.

How many INTS derivative securities does Mark A. Goldberg hold after this transaction?

After the reported grant, Mark A. Goldberg holds 5,500 stock options representing the right to buy 5,500 shares of Intensity Therapeutics common stock. The Form 4 shows these derivative securities as being held under direct ownership following the transaction.

Is Mark A. Goldberg’s INTS option grant reported as made under a Rule 10b5-1 plan?

The Form 4’s Rule 10b5-1 checkbox is not marked, so this option grant is not designated in the filing as being made pursuant to a Rule 10b5-1 trading plan. No separate trading-plan footnote is indicated for this transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/20/2026 - 04:03 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GOLDBERG MARK A

(Last) (First) (Middle)

C/O INTENSITY THERAPEUTICS, INC.

1 ENTERPRISE DRIVE, SUITE 430

(Street)

SHELTON CONNECTICUT 06484

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
INTENSITY THERAPEUTICS, INC. [ INTS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/16/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy Common Stock)	$4.9	07/16/2026		A		5,500		07/16/2026(1)	07/16/2036	Common Stock	5,500	$0	5,500	D

Explanation of Responses:

1. This option will vest, subject to the individual's continued service with Intensity Therapeutics, Inc., in four, equal, annual installments, beginning on July 16, 2026.

Remarks:

	/s/ Kostantinos Skordalos, Attorney-in-fact	07/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)